EMEA-002886-PIP02-23 - paediatric investigation plan
rocatinlimab
PIPHuman
Key facts
- Active Substance
- rocatinlimab
- Therapeutic area
- Skin and subcutaneous tissue disorders
- Decision number
- P/0023/2024
- PIP number
- EMEA-002886-PIP02-23
- Condition(s) / indication(s)
- Treatment of prurigo nodularis
- Contact for public enquiries
Amgen Europe B.V.
Tel. +44 (0)1223 420305
E-mail: pipenquiry@amgen.com- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date